Skip to main content

The senior clinical research scientist at Acumen Pharmaceuticals talked about how the company has refined Alzheimer screening in their phase 2 trial by implementing plasma p-tau 217 biomarkers which reduced amyloid-negative results and patient burden. [WATCH TIME: 5 minutes]:

Source: Neurology Read More